Achieve optimization of the manufacturing process! Simple scale-up for robust refining processes.
The "Delta Membrane T-Series TFF Cassette" employs a low protein adsorption Delta membrane, optimizing the manufacturing process. The cassette is designed to enable large volume liquid transfer to improve the customer's manufacturing process, including cost-effectiveness. The new material composition offers excellent durability and stability, with very low leachables, and the membrane can withstand back pressure up to 0.4 MPa. 【Features】 ■ Improves process performance ■ Easy scale-up for robust purification processes ■ Enhanced safety, reliability, and reproducibility ■ High permeability and selectivity, along with low protein adsorption performance *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Other Features】 ■ The supply side and permeate side screen materials use polypropylene, which has high resistance to sodium hydroxide. ■ The enlarged flow path ports on the supply side and permeate side achieve low pressure loss. ■ Designed to provide maximum mass transfer through the membrane, achieving shorter processing times with a smaller effective filtration area compared to conventional cassette-shaped products. *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Applications】 ■ Antibody fragments (Fab) ■ Purification and recovery of antibodies ■ Concentration and desalting of recombinant proteins ■ Fractionation and purification of plasma proteins *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.